Patents Assigned to Boehringer Ingelheim Pharma GmbH & Co. KG
  • Patent number: 8226982
    Abstract: The invention therefore relates to protein-containing powders, wherein the proportion of phenylalanine is at least 30% (w/w), or at least 40% (w/w). It has been shown that phenylalanine-containing powders, particularly after spray drying, are very suitable in terms of their aerodynamic characteristics and protein stabilization for preparing powders or protein compositions with improved aerodynamic properties. The main component is phenylalanine and the optional further component is an excipient which has good water-solubility compared with phenylalanine, preferably a sugar or a polyol.
    Type: Grant
    Filed: June 22, 2007
    Date of Patent: July 24, 2012
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Torsten Schultz-Fademrecht, Patrick Garidel, Beate Fischer, Karoline Bechtold-Peters
  • Patent number: 8221999
    Abstract: The invention concerns the field of protein production and cell culture technology. CERT is identified as a novel in vivo PKD substrate. Phosphorylation on serine 132 by PKD decreases the affinity of CERT towards its lipid target phosphatidylinositol 4-phosphate at Golgi membranes and reduces ceramide transfer activity, identifying PKD as a regulator of lipid homeostasis. The present invention shows that CERT in turn is critical for PKD activation and PKD dependent protein cargo transport to the plasma membrane. The interdependence of PKD and CERT is thus a key to the maintenance of Golgi membrane integrity and secretory transport.
    Type: Grant
    Filed: February 29, 2008
    Date of Patent: July 17, 2012
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Hitto Kaufmann, Lore Florin, Eric Becker, Monilola Olayioye, Angelika Hausser, Tim Fugmann
  • Patent number: 8197845
    Abstract: The invention relates to powdered preparations containing tiotropium for inhalation, processes for preparing them as well as their use in preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: June 12, 2012
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Mareke Hartig, Michael Trunk, Michael Walz
  • Patent number: 8178541
    Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R3 are as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    Type: Grant
    Filed: June 20, 2008
    Date of Patent: May 15, 2012
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Frank Himmelsbach, Elke Langkopf, Matthias Eckhardt, Michael Mark, Roland Maier, Ralf Lotz, Mohammad Tadayyon
  • Patent number: 8175843
    Abstract: Computer-implemented methods for statistical analysis and summarization of a stability study on a pharmaceutical product using of a macro integrated into statistical analysis software. The method includes inputting and summarizing data observed for a stability study on a pharmaceutical product, statistically analyzing the data, including using at least one regression function to characterize the time-response relationship of at least one stability response variable, to estimate a shelf life of the pharmaceutical product or confirm the shelf life of an existing pharmaceutical product, and providing standardized output data and graphical presentations of observed stability response data. Also, a computer loaded with a general statistical analysis software and a macro integrated with the software such that the computer is capable of performing these computer-implemented methods using the software and macro.
    Type: Grant
    Filed: November 14, 2008
    Date of Patent: May 8, 2012
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Rene Kubiak, James Schwenke, Volker Krzykalla, Hans-Juergen Lomp, Cornelia Schepers
  • Patent number: 8119648
    Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R3 are as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    Type: Grant
    Filed: June 20, 2008
    Date of Patent: February 21, 2012
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Frank Himmelsbach, Elke Langkopf, Matthias Eckhardt, Michael Mark, Roland Maier, Ralf Lotz
  • Publication number: 20120035158
    Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R4 are defined as in claim 1, the tautomers and the stereoisomers thereof, mixtures thereof, the prodrugs and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    Type: Application
    Filed: October 25, 2011
    Publication date: February 9, 2012
    Applicant: BOEHRINGER INGELHEIM PHARMA GMBH AND CO. KG
    Inventors: Frank HIMMELSBACH, Michael MARK, Matthias ECKHARDT, Elke LANGKOPF, Roland MAIER, Ralf R.H. LOTZ
  • Publication number: 20120031802
    Abstract: A method of sealing parts of a plastic capsule by forming a weld seam in an overlapping region of the parts of the capsule, wherein the capsule comprises a capsule cap having an open end and a capsule body having an open end, and capsules formed by such method. The capsules produced by the process according to the invention are disposable and preferably contain a single dose of a pharmaceutical formulation in the form of a powder or liquid intended to be administered by inhalation and are suitable by their form and function for use in powder inhalers or liquid nebulizers for producing aerosols. Aerosols thus produced can be inhaled, for example, in order to administer a pharmaceutical formulation to the lungs.
    Type: Application
    Filed: September 2, 2011
    Publication date: February 9, 2012
    Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
    Inventors: Dieter HOCHRAINER, Herbert WACHTEL
  • Publication number: 20110312029
    Abstract: The invention concerns novel regulatory elements as well as related vectors and cells. Furthermore, it relates to methods of improving expression of polypeptides from nucleic acids such as cloned genes and to the production of various polypeptides in host cells using said novel regulatory elements. Additionally, the invention relates to uses of said novel regulatory elements as insulators, in gene therapy or for improving host cell lines.
    Type: Application
    Filed: July 22, 2009
    Publication date: December 22, 2011
    Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO, KG
    Inventor: Barbara Enenkel
  • Publication number: 20110303740
    Abstract: The invention relates to a folding box made from a one-piece cardboard blank (28) comprising an integrally formed hinged lid (7) that overlaps an upper end area of a rectangular-cuboid-shaped body (1) on three sides, is connected to a rear wall (5) of the body (1) through a fold line (6), and lies flush on a front wall (4) and two side walls (3) in the closed state, and having a front panel (9) and two side panels (10) that form a collar (11) that protrudes into the hinged lid (7), wherein the front panel (9) is arranged parallel to and at a distance from the front wall (4) and divides the body (1) into a main compartment (12) and a front compartment (13).
    Type: Application
    Filed: November 11, 2009
    Publication date: December 15, 2011
    Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
    Inventor: Reinhard Schuld
  • Patent number: 8061350
    Abstract: A process and a device for dosing a pharmaceutical agent, preferably a liquid, are proposed. To achieve an enhanced dosing accuracy, a first component that is produced in batches, such as a shaped seal, is combined with a second component, such as a guide pipe selected from a suitable group guide pipes, wherein the suitable group of second components is selected based on at least one decisively significant value of the respective batch first components and is distinguished by an essential value of the second component which will optimize the sealing between the first and second components.
    Type: Grant
    Filed: June 2, 2006
    Date of Patent: November 22, 2011
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Georg Boeck, Johannes Geser, Matthias Hausmann, Hans-Juergen Koelbel, Joachim Eicher, Christian Feiertag
  • Publication number: 20110281301
    Abstract: The invention concerns the field of protein production and cell culture technology. It describes a method of producing a heterologous protein of interest in a cell comprising a. Increasing the expression or activity of a secretion enhancing gene, and b. Increasing the expression or activity of an anti-apoptotic gene, and c. Effecting the expression of said protein of interest, whereby the secretion enhancing gene is a gene encoding a protein whose expression or activity is induced during one of the following cellular processes: plasma-cell differentiation, unfolded protein response (UPR), endoplasmic reticulum overload response (EOR).
    Type: Application
    Filed: October 6, 2008
    Publication date: November 17, 2011
    Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
    Inventors: Hitto Kaufmann, Eric Becker, Lore Florin, Barbara Enenkel, Kerstin Sautter, Rebecca Bischoff
  • Publication number: 20110262967
    Abstract: The present invention refers to the area of cell culture technology and relates to methods for multiplying/cloning cells, preferably cell lines, which are important to the production of biopharmaceuticals. The invention further relates to methods for manufacturing proteins and to the use of cells extracted and multiplied through single cell sorting and to media compositions that enable a multiplication of single cells. Through the use of albumin-producing, preferably HSA-producing, cells as feeder cells for the conditioning of medium or as host cells, the recloning efficiency and thereby the quantity of clones obtained can be significantly increased. A combination of these approaches is also possible. Through the use of albumin-producing, preferably HSA-producing, cells, an increase in the recloning efficiency can be achieved in serum-free and/or insulin-free medium as well, and in different cell types.
    Type: Application
    Filed: September 9, 2009
    Publication date: October 27, 2011
    Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
    Inventors: Lore Florin, Rebecca Bischoff, Juergen Fieder, Hitto Kaufmann, Thomas Krieg
  • Patent number: 8044046
    Abstract: A pharmaceutical composition comprising a compound of formula 1 wherein: n is 1 or 2; R1 is hydrogen, C1-C4-alkyl, halogen, OH, or —O—C1-C4-alkyl; R2 is hydrogen, C1-C4-alkyl, halogen, OH, or —O—C1-C4-alkyl; R3 is hydrogen, C1-C4-alkyl, OH, halogen, —O—C1-C4-alkyl, —O—C1-C4-alkylene-COOH, or —O—C1-C4-alkylene-CO—O—C1-C4-alkyl, or an acid addition salt thereof with a pharmacologically acceptable acid, or a solvate or hydrate thereof; and a pharmaceutically acceptable excipient or carrier, and methods for using the pharmaceutical formulation in the treatment of chronic obstructive pulmonary disease (COPD).
    Type: Grant
    Filed: May 18, 2005
    Date of Patent: October 25, 2011
    Assignee: Boehringer Ingelheim Pharma GmbH & Co KG
    Inventors: Ingo Konetzki, Kurt Schromm, Hermann Schollenberger, Sabine Pestel, Andreas Schnapp, Thierry Bouyssou, Frank Buettner, Claudia Heine, Philipp Lustenberger, Christoph Hoenke, Klaus Rudolf
  • Publication number: 20110257215
    Abstract: The invention relates to a new crystalline form of tiotropium bromide, processes for preparing it and its use for preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.
    Type: Application
    Filed: November 13, 2007
    Publication date: October 20, 2011
    Applicant: Boehringer Ingelheim Pharma GmbH CO.KG
    Inventors: Stephen Watt, Alexander R. Eberlin
  • Publication number: 20110250640
    Abstract: A new method for selecting clones and recloning mammalian cells which are of importance for the production of biopharmaceuticals, preferably hamster or mouse myeloma cells, with a high degree of automation and throughput. The invention relates to methods of depositing and replicating single cell clones of the cells in question. The invention also relates to methods of preparing proteins using cells which have been obtained and replicated by single cell deposition as well as compositions which allow the replication of single cells.
    Type: Application
    Filed: October 7, 2010
    Publication date: October 13, 2011
    Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
    Inventors: Ralf OTTO, Barbara ENENKEL, Juergen FIEDER, Thomas KRIEG
  • Publication number: 20110230642
    Abstract: The present invention relates to the field of cell culture technology and relates to methods of replicating/cloning cells, preferably cell lines which are important for the production of biopharmaceuticals. The invention also relates to methods of preparing proteins using cells that have been obtained and replicated by single cell deposition and compositions which make it possible to replicate individual cells. By using IGF particularly in conjunction with HSA in the culture medium after recloning, the recloning efficiency and hence the quantity of clones obtained can be increased significantly.
    Type: Application
    Filed: March 16, 2009
    Publication date: September 22, 2011
    Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
    Inventors: Juergen Fieder, Lore Florin, Hitto Kaufmann, Thomas Krieg, Melanie Briegel
  • Patent number: 8022082
    Abstract: An inhalation kit comprising: (a) an inhaler displaying a flow resistance of about 0.01 to 0.1 ?{square root over (kPa)} min/L; and (b) an inhalable powder comprising tiotropium in admixture with a physiologically acceptable excipient with an average particle size of between 10 to 500 ?m, and a method of administering an inhalable powder containing tiotropium in admixture with a physiologically acceptable excipient with an average particle size of between 10 ?m to 500 ?m, the method comprising actuating an inhaler a flow resistance of about 0.01 to 0.1 ?{square root over (kPa)} min/L containing the inhalable powder.
    Type: Grant
    Filed: June 28, 2006
    Date of Patent: September 20, 2011
    Assignee: Boehringer Ingelheim Pharma GmbH & Co., KG
    Inventor: Bernd Zierenberg
  • Patent number: 8008495
    Abstract: The invention relates to a new process for preparing tiotropium salts of general formula 1 wherein X? may have the meanings given in the claims and in the specification.
    Type: Grant
    Filed: January 5, 2009
    Date of Patent: August 30, 2011
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Ralf Lock, Werner Belzer, Rainer Hamm, Monika Hofmann
  • Patent number: RE43431
    Abstract: A compound of general formula I wherein: Ra is a benzyl, 1-phenylethyl, or 3-chloro-4-fluorophenyl group; Rb is a dimethylamino, N-methyl-N-ethylamino, diethylamino, N-methyl-N-isopropylamino, N-methyl-N-cyclopropylamino, N-methyl-N-(2-methoxyethyl)amino, N-ethyl-N-(2-methoxyethyl)amino, bis(2-methoxyethyl)amino, morpholino, N-methyl-N-(tetrahydrofuran-3-yl)amino, N-methyl-N-(tetrahydrofuran-2-ylmethyl)amino, N-methyl-N-(tetrahydrofuran-3-ylmethyl)amino, N-methyl-N-(tetrahydropyran-4-yl)amino, or N-methyl-N-(tetrahydropyran-4-ylmethyl)amino group; and Rc is a cyclopropylmethoxy, cyclobutyloxy, cyclopentyloxy, tetrahydrofuran-3-yloxy, tetrahydrofuran-2-ylmethoxy, tetrahydrofuran-3-ylmethoxy, tetrahydropyran-4-yloxy, or tetrahydropyran-4-ylmethoxy group, or a tautomer, stereoisomer, or salt thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, in particular an inhibitory effect on signal transduction med
    Type: Grant
    Filed: August 18, 2009
    Date of Patent: May 29, 2012
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Frank Himmelsbach, Elke Langkopf, Stefan Blech, Birgit Jung, Anke Baum, Flavio Solca